EA202091295A1 - Препарат - Google Patents
ПрепаратInfo
- Publication number
- EA202091295A1 EA202091295A1 EA202091295A EA202091295A EA202091295A1 EA 202091295 A1 EA202091295 A1 EA 202091295A1 EA 202091295 A EA202091295 A EA 202091295A EA 202091295 A EA202091295 A EA 202091295A EA 202091295 A1 EA202091295 A1 EA 202091295A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- drug
- polysorbate
- glycine
- binds
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1719447.3A GB201719447D0 (en) | 2017-11-23 | 2017-11-23 | Pharmaceutical composition |
| PCT/EP2018/081129 WO2019101582A1 (en) | 2017-11-23 | 2018-11-13 | Formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091295A1 true EA202091295A1 (ru) | 2020-09-03 |
Family
ID=60950516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091295A EA202091295A1 (ru) | 2017-11-23 | 2018-11-13 | Препарат |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11857625B2 (https=) |
| EP (1) | EP3713602A1 (https=) |
| JP (1) | JP6955632B2 (https=) |
| KR (1) | KR102767553B1 (https=) |
| CN (1) | CN111511399A (https=) |
| AR (1) | AR113534A1 (https=) |
| AU (1) | AU2018371056B2 (https=) |
| BR (1) | BR112020009866A2 (https=) |
| CA (1) | CA3082832C (https=) |
| CL (1) | CL2020001307A1 (https=) |
| CO (1) | CO2020006120A2 (https=) |
| EA (1) | EA202091295A1 (https=) |
| GB (1) | GB201719447D0 (https=) |
| IL (1) | IL274719B2 (https=) |
| MX (1) | MX2020004747A (https=) |
| MY (1) | MY194682A (https=) |
| RU (1) | RU2020120547A (https=) |
| SG (1) | SG11202004601YA (https=) |
| WO (1) | WO2019101582A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| CN110585430B (zh) * | 2019-09-29 | 2023-09-08 | 华博生物医药技术（上海）有限公司 | 一种人源化抗人il-17a单克隆抗体的药物组合物 |
| CN112915201B (zh) * | 2019-12-06 | 2023-06-27 | 珠海市丽珠单抗生物技术有限公司 | 包含抗il-17抗体的液体制剂 |
| CN113769082A (zh) * | 2020-06-10 | 2021-12-10 | 上海君实生物医药科技股份有限公司 | 抗il-17a抗体药物组合物及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007019232A2 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| GB0620729D0 (en) * | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| WO2009120684A1 (en) | 2008-03-25 | 2009-10-01 | Medimmune, Llc | Antibody formulation |
| MX2012007676A (es) | 2009-12-29 | 2012-08-03 | Hoffmann La Roche | Nueva formulacion de anticuerpo. |
| HRP20171939T1 (hr) | 2010-01-15 | 2018-03-23 | Kirin-Amgen, Inc. | Formulacija protutijela i režimi terapije |
| US9956165B2 (en) | 2010-03-01 | 2018-05-01 | Cytodyn Inc. | Concentrated protein formulations and uses thereof |
| SMT202000095T1 (it) * | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| FR2962650B1 (fr) | 2010-07-19 | 2013-04-05 | Lab Francais Du Fractionnement | Composition d'immunoglobulines humaines concentrees |
| MX362591B (es) * | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| SG10201510762YA (en) * | 2011-01-14 | 2016-01-28 | Ucb Pharma Sa | Antibody molecules which bind il-17a and il-17f |
| PE20150190A1 (es) * | 2012-06-21 | 2015-02-13 | Ucb Pharma Sa | Formulacion farmaceutica |
| CN107148283A (zh) * | 2014-10-31 | 2017-09-08 | 豪夫迈·罗氏有限公司 | 抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法 |
| AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CA2995222C (en) | 2015-08-19 | 2021-07-13 | Medimmune, Llc | Stable anti-ifnar1 formulation |
| MY206805A (en) | 2015-10-27 | 2025-01-08 | UCB Biopharma SRL | Methods of treatment using anti-il-17a/f antibodies |
| GB201522391D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
| US20190060241A1 (en) | 2016-04-13 | 2019-02-28 | Medimmune, Llc | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| KR102329490B1 (ko) | 2016-09-14 | 2021-11-23 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Ｉｌ-１７ａ에 특이적으로 결합하는 항체 및 그의 기능성 단편 |
-
2017
- 2017-11-23 GB GBGB1719447.3A patent/GB201719447D0/en not_active Ceased
-
2018
- 2018-11-13 JP JP2020527951A patent/JP6955632B2/ja active Active
- 2018-11-13 MY MYPI2020002408A patent/MY194682A/en unknown
- 2018-11-13 BR BR112020009866-3A patent/BR112020009866A2/pt unknown
- 2018-11-13 IL IL274719A patent/IL274719B2/en unknown
- 2018-11-13 AU AU2018371056A patent/AU2018371056B2/en active Active
- 2018-11-13 CA CA3082832A patent/CA3082832C/en active Active
- 2018-11-13 EA EA202091295A patent/EA202091295A1/ru unknown
- 2018-11-13 SG SG11202004601YA patent/SG11202004601YA/en unknown
- 2018-11-13 WO PCT/EP2018/081129 patent/WO2019101582A1/en not_active Ceased
- 2018-11-13 EP EP18807571.7A patent/EP3713602A1/en active Pending
- 2018-11-13 KR KR1020207017469A patent/KR102767553B1/ko active Active
- 2018-11-13 US US16/765,786 patent/US11857625B2/en active Active
- 2018-11-13 MX MX2020004747A patent/MX2020004747A/es unknown
- 2018-11-13 RU RU2020120547A patent/RU2020120547A/ru unknown
- 2018-11-13 CN CN201880075625.0A patent/CN111511399A/zh active Pending
- 2018-11-22 AR ARP180103417A patent/AR113534A1/es unknown
-
2020
- 2020-05-18 CL CL2020001307A patent/CL2020001307A1/es unknown
- 2020-05-18 CO CONC2020/0006120A patent/CO2020006120A2/es unknown
-
2023
- 2023-12-22 US US18/394,323 patent/US20240123065A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020009866A2 (pt) | 2020-11-17 |
| AU2018371056A1 (en) | 2020-06-04 |
| MY194682A (en) | 2022-12-14 |
| JP6955632B2 (ja) | 2021-10-27 |
| CA3082832A1 (en) | 2019-05-31 |
| JP2021504321A (ja) | 2021-02-15 |
| CA3082832C (en) | 2023-07-18 |
| EP3713602A1 (en) | 2020-09-30 |
| AR113534A1 (es) | 2020-05-13 |
| AU2018371056B2 (en) | 2024-06-20 |
| CO2020006120A2 (es) | 2020-05-29 |
| IL274719A (en) | 2020-07-30 |
| WO2019101582A1 (en) | 2019-05-31 |
| RU2020120547A (ru) | 2021-12-23 |
| GB201719447D0 (en) | 2018-01-10 |
| US11857625B2 (en) | 2024-01-02 |
| KR20200090829A (ko) | 2020-07-29 |
| MX2020004747A (es) | 2020-08-20 |
| US20210106683A1 (en) | 2021-04-15 |
| KR102767553B1 (ko) | 2025-02-12 |
| RU2020120547A3 (https=) | 2021-12-23 |
| CL2020001307A1 (es) | 2020-10-16 |
| IL274719B1 (en) | 2024-06-01 |
| US20240123065A1 (en) | 2024-04-18 |
| SG11202004601YA (en) | 2020-06-29 |
| CN111511399A (zh) | 2020-08-07 |
| IL274719B2 (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091295A1 (ru) | Препарат | |
| MX2022006759A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| EA201891694A1 (ru) | Фармацевтическая композиция, содержащая конструкты биспецифических антител | |
| JOP20200312A1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| EA201991876A1 (ru) | Антитела против фактора d и их применения | |
| BR112015022260A2 (pt) | anticorpo monoclonal, polinucleotídeo, composição farmacêutica, fragmento isolado de tau, uso de um anticorpo, método de triagem de um agente e ácido nucleico | |
| EA202191806A1 (ru) | Антитело против человеческого il-4ra и его применение | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| EA202191763A1 (ru) | Бифункциональная молекула анти-pd-1/sirp | |
| DK3576788T3 (da) | Farmaceutisk sammensætning med lavt ph, der omfatter t-celle-engagerende antistofkontruktioner | |
| MX381232B (es) | Formulación de anticuerpos. | |
| JOP20190096B1 (ar) | مركبات ببتيد تيروسين-تيروسين الحلقية المقترنة بجسم مضاد كمعدلات لمستقبلات الببتيد العصبي y | |
| EA202192146A1 (ru) | Антитела к клаудину 6 и их применение | |
| EA202192405A1 (ru) | Составы антител против il-36r | |
| EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
| MX2018015274A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
| SA523450918B1 (ar) | أجسام مضادة للنكتين-4 واستخداماتها | |
| EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
| CL2020002459A1 (es) | Variantes de anticuerpo c-terminales | |
| EP3947466A4 (en) | ANTI-HLA-DQ2.5 ANTIBODIES | |
| EA202092508A1 (ru) | Составы на основе антител к pd-l1 человека | |
| EP3805390A4 (en) | NAV1.7 MONOCLONAL ANTIBODY | |
| MX421763B (es) | Metodos y composiciones que comprenden proteina d tensoactiva (sp-d) | |
| CO2020015124A2 (es) | Anticuerpo anti-tlr7 humano | |
| PH12020551618A1 (en) | Erenumab compositions and uses thereof |